Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
21 citations
,
January 2015 in “The Journal of Steroid Biochemistry and Molecular Biology” Progesterone byproduct 5αP stimulates mammary tumor growth, but finasteride can suppress it.
May 2019 in “CINECA IRIS Institutial Research Information System (University of Genoa)” MITF+ melanoma patients are more likely to have multiple melanomas and unique skin patterns.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
24 citations
,
December 2011 in “International Journal of Cancer” PTH-CBD agonists may help regrow hair after chemotherapy.
57 citations
,
January 2022 in “Biomedicines” Curcumin may improve cancer radiotherapy by making cancer cells more sensitive to radiation and protecting normal cells.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
July 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The study developed a 3D model that closely imitates remaining ovarian cancer after treatment and identified a potential drug targeting resistant cancer cells.
9 citations
,
January 2023 in “Cellular and Molecular Life Sciences” Botulinum toxin A can help improve thin endometrium and embryo implantation.
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
May 2022 in “Голова и шея.” Exosomes show promise for targeted treatment of HER2-positive breast cancer.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
April 2026 in “Clinical and Experimental Dermatology” The Dupilumab Italian Prurigo Nodularis (DUPItaPN) study evaluated the long-term effectiveness and safety of dupilumab in 543 adults with prurigo nodularis (PN) over 104 weeks. The study found that dupilumab significantly improved symptoms, with the mean Worst Itch Numeric Rating Scale (WI-NRS) score decreasing from 8.7 to 1.7, and 86.8% of patients achieving a ≥4-point reduction by week 104. Additionally, 81.2% of patients reached an Investigator Global Assessment for PN-Stage (IGA PN-S) of 0/1. The Dermatology Life Quality Index (DLQI) improved from 17.4 to 2.6. Dupilumab was well tolerated, with only 2.9% discontinuing due to adverse events, and no cancer progression or viral reactivation observed. The study supports dupilumab as a long-term treatment option for moderate-to-severe PN, even in elderly and comorbid patients.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
10 citations
,
March 2022 in “Frontiers in Oncology” HOTTIP and miR-10b contribute to glioma therapy resistance by affecting cell behavior, suggesting they could be targets for treatment.
10 citations
,
December 2008 in “Molecular Carcinogenesis” The PML protein helps prevent skin cancer in mice.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.